The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.
The International Generic and Biosimilar Medicines Association (IGBA) has launched the first Global Biosimilars Week, an attempt to raise awareness of the value of biosimilars and provide resources for interested persons to find out more about these lower-cost agents
The website for Global Biosimilars Week contains patient testimonials, an introductory overview of biosimilars, and various other resources designed to explain the global reach biosimilars have achieved and their importance for extending treatment options.
“Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support healthcare systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Hanan Sboul, chair of the IGBA.
IGBA is based in Geneva and is a trade association of companies that develop and market biosimilar medicines, which are often sold at significant discounts to innovator biologics and help to increase access to treatment for patients.
Global Biosimilars Week will continue through Friday, November 20. “Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support health care systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Erika Satterwhite, chair of the IGBA biosimilars Committee.
The group is inviting interested members of the public to join an online discussion about biosimilars on social media this week using the hashtag #GlobalBiosimilarsWeek.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.